Pharmacotherapy for arterial hypertension in pregnant women: analysis of the results of Register of pregnancy «BEREG»


DOI: https://dx.doi.org/10.18565/therapy.2020.1.32-43

Stryuk R.I., Brytkova Ya.V., Gomova T.A., Filippova M.P., Barkova E.L.

1) A.I. Yevdokimov Moscow State University of medicine and dentistry of the Ministry of Healthcare of Russia; 2) LLC «Medilux-TM», Moscow; 3) Tula regional clinical hospital
Based on the results of the observational study (Register of pregnancy «BEREG») was found, that from 3214 pregnant women included in the register (according to the criteria of inclusion/non-inclusion), whose age was 28 year [25; 33], 451 (14,0%) women had different clinical variants of the arterial hypertension (AH): preeclampsia, chronic AH and gestational AH. Cases of eclampsia hadn’t been registered.
Almost 70% of these patients had obesity, 40% – diabetes mellitus (DM) 2 and gestational diabetes, 36% –anemia. 62% of patients received antihypertensive therapy (AHT) by approved for use drugs for pregnant (methyldopa, nifedipine with a slow release of the active substance, bisoprolol). The original blood pressure was higher and met the criteria for the assignment of AGT, as compared with pregnant women without drug therapy. The analysis of the course of pregnancy and pregnant women’s perinatal outcomes, who was taking antihypertensive drugs (1st group) and without drug therapy (2nd group) showed that placental insufficiency was diagnosed equally often in 1/4 of women of both groups. But the treat of termination of pregnancy complicated the course of gestation in pregnant women 2nd group in 2,3 times more often than in patients with AH taking AHT. At the same time, at the same time, premature birth and complications in the new born, as well as lower body weight of the newborn, were significantly more frequent for women of 1st group than of the 2nd, what can be associated with a more serve course of the AH. Probability analysis of the influence of antihypertensive drugs on the children birth with congenital heart diseases didn’t find any links. But all mothers with AH were with comorbid pathology – obesity and carbohydrate metabolism.
Keywords: newborn condition, perinatal outcomes, congenital malformations, pharmacotherapy, pregnancy, arterial hypertension
Read entire article

Literature


  1. Стрюк Р.И., Бернс С.А., Филиппова М.П., Брыткова Я.В., Борисов И.В., Баркова Е.Л., Гомова Т.А., Козина Е.А., Нагирняк О.А. Сердечно-сосудистые заболевания и ассоциированные с ними коморбидные состояния как факторы, определяющие неблагоприятные перинатальные исходы при беременности – анализ данных регистра беременных «БЕРЕГ». Терапевтический архив. 2018; 1(90): 9–16. [Stryuk R.I., Berns S.A., Filippova M.P., Brytkova Ya.V., Borisov I.W., Barkova E.L., Gomova T.A., Kozina E.A., Nagirnyak O.A. Cardiovascular diseases and comorbid conditions associated with them as factors determining adverse perinatal outcomes during pregnancy - analysis of data from the pregnant registry «BEREG». Ter. Arkhiv. 2018; 1(90): 9–16 (in Russ.)]. doi: 10.17116/terarkh20189019-1

  2. James P.R., Nelson-Piercy C. Management of hypertension before, during and after pregnancy. Heart. 2004; 90: 1499–504.doi: 10.1136/hrt.2004.035444

  3. Тарасова О.А., Чулков В.С., Синицын С.П., Вереина Н.К. и др. Факторы кардиометаболического риска у женщин с анамнезом артериальной гипертензии во время беременности. Артериальная гипертензия. 2019; 25(1): 97–104. [Tarasova O.A., Chulkov V.S., Sinitsyn S.P., Vereina N.K. et al. Cardiometabolic risk factors in women with a history of hypertension during pregnancy. Arterialnaya gipertenziya. 2019; 25(1): 97–104 (in Russ.)]. doi: 10.18705/1607-419X-2019-25-1-97-104

  4. Диагностика и лечение сердечно-сосудистых заболеваний при беременности – 2018: Национальные рекомендации. Российский кардиологический журнал. 2018; 3: 91–134. [Diagnosis and treatment of cardiovascular disease during pregnancy 2018: National recommendations. Rossiiskii kardiologicheskii zhurnal. 2018; 3: 91–134 (in Russ.)]. doi: 10.15829/1560-4071-2018-3-91-134

  5. Ягудина Р.И., Литвиненко М.М., Сороковиков И.В. Регистры пациентов: структура, функции, возможность использования. Фармакоэкономика. 2011; 4(4): 3–7. [Yagudina R.I., Litvinenko M.M., Sorokovikov I.V. Patients registry: structure, functions, opportunities of appliance. Pharmacoeconomics. 2011; 4(4): 3–7 (in Russ.)]. https://cyberleninka.ru/article/v/registry-patsientov-struktura-funktsii-vozmozhnosti-ispolzovaniya

  6. Стрюк Р.И., Брыткова Я.В., Бернс С.А., Баркова Е.Л. и др. Артериальная гипертония как фактор риска осложненного течения беременности и неблагоприятных перинатальных исходов — анализ регистра беременных БЕРЕГ. Кардиологический вестник. 2018; 13(1): 16–22. [Stryuk R.I., Brytkova Ya.V., Berns S.A., Barkova E.L. et al. Arterial hypertension as a risk factor for the complicated course of pregnancy and adverse perinatal outcomes - analysis of the register of pregnant BEREG. Kardiologicheskii vestnik. 2018; 13(1): 16–22 (in Russ.)]. doi: 10.17116/Cardiobulletin201813116-22

  7. Webster L.M., Conti-Ramsden F., Seed P.T., Webb A.J., Nelson-Piercy C., Chappell L.C. Impact of antihypertensive treatment on maternal and perinatal outcomes in pregnancy complicated by chronic hypertension: a systematic review and meta-analysis. J Am Heart Assoc. 2017; 6(5). pii: e005526. doi: 10.1161/JAHA.117.005526.

  8. Баранов А.А., Намазова-Баранова Л.С., Альбицкий В.Ю., Терлецкая Р.Н. Закономерности и тенденции младенческой и детской смертности в Российской Федерации. Проблемы социальной гигиены и история медицины. 2015; 1: 35–41. [Baranov A.A., Namazova-Baranova L.S., Albitskii V.Yu., Terletskaia R.N. The regularities and tendencies of infant and children mortality in the russian federation. Problemy social’noj gigieny i istorija mediciny. 2015; 1: 35–41 (in Russ.)]. https://cyberleninka.ru/article/n/zakonomernosti-i-tendentsii-mladencheskoy-i-detskoy-smertnosti-v-rossiyskoy-federatsii

  9. Dunietz G.L., Strutz K.L., Holzman C. et al. Moderately elevated blood pressure during pregnancy and odds of hypertension later in life: the POUCH moms’ longitudinal study. BJOG. 2017; 124(10): 1606–13. doi: 10.1111/1471-0528.14921

  10. Leslie M.S., Briggs L.A. Preeclampsia and the risk of future vascular disease and mortality: a review. J Midwifery Womens Health. 2016; 61(3): 315–24. doi: 10.1111/jmwh.12469

  11. Ayansina D., Black C., Hall S.J. et al. Long-term effects of gestational hypertension and pre-eclampsia on kidney function: Record linkage study. Pregnancy Hypertens. 2016; 6(4): 344–49. doi: 10.1016/j.preghy.2016.08.231

  12. Hajer G.R., wan Haeften T.W., Visseren F.L. Adipose tissue disfunction in obesity, diabetes and vascular diseases. Eur. Heart J. 2008; 29(24): 2959–71. doi: 10.1093/eurheartj/ehn387

  13. Villa P.M., Marttinen P., Gillberg J., Lokki A.I. et al. Cluster analysis to estimate the risk of preeclampsia in the high-risk Prediction and Prevention of Preeclampsia and Intrauterine Growth Restriction (PREDO) study. PLoS One. 2017; 12(3): e0174399.doi: 10.1371/journal.pone.0174399

  14. Abalos E., Duley L., Steyn D.W., Gialdini C. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2018; 10: CD002252. doi: 10.1002/14651858.cd002252.pub4

  15. Ramakrishnan A., Lee L.J., Mitchell L.E. Maternal hypertension during pregnancy and the risk of congenital heart defects in offspring: a systematic review and meta-analysis. Agopian AJ Pediatr Cardiol. 2015; 36(7): 1442–51. doi: 10.1007/s00246-015-1182-9

  16. Fitton C.A., Steiner M.F.C., Aucott L., Pell J.P. et al. In-utero exposure to antihypertensive medication and neonatal and child health outcomes: a systematic review. J Hypertens. 2017; 35(11): 2123–37. doi: 10.1097/HJH.0000000000001456

  17. Boesen E.I. Consequences of in-utero exposure to antihypertensive medication: the search for definitive answers continues. J Hypertens. 2017; 35(11): 2161–64. doi: 10.1097/HJH.0000000000001486

  18. Magee L.A., von Dadelszen P., Singer J., Lee T. et al. Do labetalol and methyldopa have different effects on pregnancy outcome? Analysis of data from the Control of Hypertension In Pregnancy Study (CHIPS) trial. Int J of Obstet Gynaecol. 2015; 123(7): 1143–51. doi: 10.1111/1471-0528.13569

  19. Yakoob M.Y., Bateman B.T., Ho E., Hernandez-Diaz S. et al. The risk of congenital malformations associated with exposure to β-blockers early in pregnancy: a meta-analysis. Hypertension. 2013; 62(2): 375. doi: 10.1161/hypertensionaha.111.00833

  20. Fisher S.C., Van Zutphen A.R., Werler M.M., Lin A.E. et al. Maternal antihypertensive medication use and congenital heart defects: updated results from the national birth defects prevention study. Hypertension. 2017; 69(5): 798–805.doi: 10.1161/hypertensionaha.116.08773

  21. Bateman B.T., Heide-Jørgensen U., Einarsdóttir K., Engeland A. et al. β-blocker use in pregnancy and the risk for congenital malformations: an international cohort study. Ann Intern Med. 2018; 169(10): 665. doi: 10.21037/pm.2018.ab002

  22. Duan L., Ng A., Chen W., Spencer H.T. et al. β-Blocker Exposure in Pregnancy and Risk of Fetal Cardiac Anomalies. JAMA Intern Med. 2017; 177(6): 885. doi: 10.1001/jamainternmed.2017.0608


About the Autors

Raisa I. Stryuk, MD, professor, honored doctor of the Russian Federation, head of the Department of internal medicine of the Faculty of dentistry of A.I. Yevdokimov Moscow State University of medicine and dentistry of the Ministry of Healthcare of Russia. Address: 127473, Moscow, 20/1 Delegatskaya Str. Tel.: +7 (903) 565-73-88. E-mail: rstryuk@list.ru
Yana V. Brytkova, MD, specialist of ultrasound diagnostics of LLC «Medilux-TM». Address: 119019, Moscow, 8/4 bld. 2 Lebyazhy Lane. Tel.: +7 (916) 295-58-54. E-mail: yabrytkova@yandex.ru
Tatyana A. Gomova, PhD, Deputy Chief physician of Tula regional clinical hospital. Address: 300053, Tula, 1a Yablochkova Str. Tel.: +7 (905) 115-05-51. E-mail: tatyana-gomova@yandex.ru
Marina P. Filippova, PhD, associated professor of the Department of internal medicine of the Faculty of dentistry of A.I. Yevdokimov Moscow State University of medicine and dentistry of the Ministry of Healthcare of Russia. Address: 127473, Moscow, 20/1 Delegatskaya Str. Tel.: +7 (915) 155-03-03. E-mail: mpfil0509@gmail.com
Elena L. Barkova, assistant of the Department of internal medicine of the Faculty of dentistry of A.I. Yevdokimov Moscow State University of medicine and dentistry of the Ministry of Healthcare of Russia. Address: 127473, Moscow, 20/1 Delegatskaya Str. Tel.: +7 (903) 747-97-65. E-mail: elbarkova@mail.ru


Similar Articles

Back to Content

Бионика Медиа